Correlation between Nicotinamide Phosphoribosyl Transferase (NAMPT) level and clinicopathological criteria in colorectal cancer patients

Madeha M. Zakhary1, Ashraf M. Albadry2, Samer A. Alsawy3, Alia Kh. Mahmoud3
Departments of Biochemistry1,3 & General Surgery2 Faculty of Medicine, Assiut1 and Sohag University2,3.

Abstract

Background: Colorectal cancer (CRC) is one of the most common cancers worldwide, with the highest incidence rates in western countries. The 5-year survival rate for a patient diagnosed with stage I or II colorectal cancer, is up to 90%. However, the 5-year survival rate for patients diagnosed with stage IV disease, once the cancer has metastasized to other organs, is only 12%.

Aim of the work: is to detect levels of Visfatin, Nitric oxide, Lipid peroxide and Superoxide dismutase in serum of patients with colorectal cancer and compare results with patients with benign colorectal tumor and with control group and detect the relation of each of them to the clinic-pathological criteria in colorectal cancer.

Patients and methods: This study was performed at Sohag University Hospital from December 2015 to June 2016, eighty-five persons were enrolled in the study and divided into three groups. 60 patients with colorectal cancer, 10 patients with benign colorectal tumors all of them were selected from Sohag Cancer Institute and Sohag University Hospital and 15 healthy persons of matched age and sex without evidence of any cancer (controls). All were matched for age and sex, for each participant complete medical history, physical examination, and routine investigations were done. Nicotinamide phosphoribosyltransferase (NAMPT) was measured by Eliza kits. Nitric oxide and Superoxide dismutase (SOD) activities level were measured by colorimetry.

Results: The serum levels of visfatin "NAMPT", NO and lipid peroxidation products as "MDA" in patients with benign tumor were significantly higher than in healthy controls, in patients with colorectal cancer the levels are significantly higher than in healthy controls and patients with benign tumor (p-value < 0.001), and there is significant relations between levels of NAMPT and the clinicopathological criteria of the cancer. In contrast the levels of antioxidant enzyme (superoxide dismutase) were "decreased" in colorectal cancer group, benign lesions group comparing to healthy control group.

Conclusion: our study relieved that there is positive relation between level of visfatin and colorectal cancer occurrence and cancer clinicopathological criteria. Also our study relieved that colorectal carcinogenesis is associated with serious oxidative stress and confirms that gradual advancement of oxidative-antioxidative disorders is followed by progression of colorectal cancer.

Keywords: NAMPT, oxidants, antioxidant activity, Colorectal cancer.
E-mail: aliakhairy88@gmail.com. Tel: 01023742566.

Introduction

Colorectal cancer is the third most common cancer and the third leading cause of cancer death expected to occur in both men and women in the United States in 2014 (1) and accounted for almost 10% of global cancer incidence burden in 2012 (2).

Colorectal cancer is one of the most common cancers in the world, with over 1.2 million new cases diagnosed each year (3). Despite improvements in screening for early diagnosis, colorectal cancer...
remains one of the biggest cancer killers in the world and is responsible for over 600,000 deaths each year (3). Initially, it is developed as a benign precursor lesion (adenoma), which can progress to an invasive lesion (adenocarcinoma) with the capacity to metastasize (metastatic adenocarcinoma).

The 5-year survival rate of this disease is approximately 90% for patients with localized disease and approximately 66% for patients with regional disease, as determined at diagnosis (4).

Also, known in the literature as visfatin or pre-B cell enhancing factor (PBEF) which was isolated from peripheral blood lymphocytes and described as a secreted growth factor for early B cell proliferation (5) possesses many important functions for cellular pathophysiology being an insulin-mimetic adipokine which is highly expressed and secreted by visceral adipose tissue, associated with obesity (6). Furthermore, Nampt is the rate-limiting enzyme that converts nicotinamide into NAD$^+$ which is essential for cellular metabolism, energy production, DNA repair, and survival (7). It is well known that cancer cells have a higher basal turnover of NAD and display higher energy requirements compared with non-malignant cells. Increasing evidence demonstrated that Nampt acts as a multifunctional enzyme and is important for the metabolism and immune response as well as cancer disease development (8).

The dysregulation of NAMPT gene as well as abnormalities in circulating NAMPT levels have been implicated in the susceptibility and pathogenesis of a number of human diseases and pathologic conditions, NAMPT has been implicated in cancer as breast cancer, colorectal cancer, gastric cancer, prostatic cancer, brain tumors and ovarian cancer, obesity, aging, atherosclerosis, sepsis, acute lung injury, rheumatoid arthritis (9).

Nampt was first reported to be overexpressed in colorectal cancer using suppression subtractive hybridization (10). Additionally, plasma Nampt levels in patients with advanced and early cancer were higher than in controls (11). However, the expression of Nampt in both of human colorectal adenoma and carcinoma tissues was not explored yet. Furthermore, whether Nampt expression is associated with clinicopathological characteristics in colorectal carcinoma tissue is unknown. There is growing support for the concept that reactive oxygen species (ROS) which are known to be implicated in a range of diseases, may be important progenitors in carcinogenesis (12). In the last decade, growing number of reports investigating association between ROS and carcinogenesis have been published (12, 13, 14). However, recent evidence has suggested that the generation of ROS may play important role in all phases of carcinogenesis, that is, the initiation, promotion, and progression stages (12).

DNA damage can result in either cell cycle arrest or induction of transcription, induction of signal transduction pathways, replication errors, and genomic instability, all of which are associated with colon carcinogenesis (12).

**Aim of the work**

The aim of the present study is to:
- 1-Evaluate the levels of (NAMPT) in patients with colorectal adenomas and carcinomas.
- 2-Detect whether NAMPT levels is correlated with clinicopathologicalcritiria in colorectal tumors.
- 3-Detect oxidative stress status in patients with colorectal cancer byestimatingthelevels nitric oxide and
that of final lipid peroxidation products like (MDA) malondialdehyde.

4-Detect antioxidant status in patients with colorectal cancer be estimating level of antioxidative enzymes as superoxide dismutase (SOD).

**Patientes and method**

This study was performed at Sohag University Hospital from December 2015 to June 2016, The study was approved by the ethics committee of Sohag faculty of Medicine and informed consents were obtained from all individuals included in the study. All individuals were informed regarding the tests and their clinical meanings before the study.

**I - patients:**

Our study included; 70 patients with colorectal tumors who were selected from Sohag Cancer Institute and Sohag University Hospital. They were divided into 2 groups according to the type of the tumor:
- Group I patients with malignant tumor (n=60).
- Group II patients with benign tumor (n=10).

The control group (n=15).

Complete medical history, physical examination, and routine investigations were done for all participants: Complete blood count (CBC), Kidney function test and Liver function test. All patients were subjected to abdominal computer tomography, magnetic resonance imaging and upper and lower endoscopy when required. The colorectal cancer was classified according to TNM staging system.

In addition, they were classified according to the size of cancer into high tumor burden (>6x6 cm) and low tumor burden (≤6x6 cm).

**Exclusion critiria**

Primary tumors in other organs, hereditary cancer syndrome, previous malignancy, previous radiotherapy or chemotherapy were excluded from the study.

**II -Methods:**

Random venous blood samples were withdrawn from patients and control persons, and then centrifuged in centrifuge system for 20 minutes. Serum was removed then the samples were stored in aliquot at -20 °C until assay.

1-**NAMPT (Visfatin)**

Visfatin was measured by test kits supplied by WKEA MED SUPPLIES CROP (code NO: WH-1525) which allow determination of human Visfatin concentration in human serum using an enzyme linked immunosorbent assay (ELISA) for detection of Visfatin.

2-**Nitric oxide**

By Griess method we do colometric determination of nitrite supplied by Bio Diagnostic Company.

In acid, medium and in presence of nitrite the formed nitrous acid diazotisesulphanilamide and the product is coupled with N-(1-naphthyl) ethylenediamine. the resulting azo dye has a bright reddish-purple color which can be measured at 540 nm.

3-**Measurement of Lipid peroxide (MDA) levels.**

MDA levels were measured according to the manufacturers instructions (bio diagnostic; Pharmaceutical Industries, CAT. No. MD 25 29, Egypt). Thiobarbituric acid (TBA) reacts with MDA in acidic medium at temperature of 95°C for 30 min to form thiobarbituric acid reactive product the absorbance of the resultant pink product can be measured at 534 nm.

4-**Measurement of SOD activities**

Superoxide dismutase activities were measured according to the manufacturer's instructions (Biodiagnostic; Pharmaceutical Industries, CAT. No. SD 25 21, Egypt). This assay relies on the ability of the enzyme to inhibit the
phenazinemethosulphate- mediated reduction of nitrobluetetrazolium dye.

**Statistical analysis:**
Data was analyzed using SPSS computer program version 22.0. Quantitative data was expressed as means ± standard deviation, median and range. Qualitative data was expressed as number and percentage. The data were tested for normality using Kolmogrov–Smirnov test which was significant indicating the use of nonparametric tests as data wasn't normally distributed. The nonparametric Mann–Whitney test was used for comparing two quantitative variables. Kruskal–Wallis test was used for comparison between more than two quantitative variables. Chi-Square test or Fisher's Exact test were used for comparison between qualitative variables. Spearman's correlation coefficient was used for measuring correlation between the different enzymes levels.

**Resultes**

Table (1): Comparison of the three studied groups by socio demographic characteristics, family history and chronic illness (N. =85)

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Malignant tumor (N=60)</th>
<th>Benign tumor (N=10)</th>
<th>Healthy control (N=15)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>46.2 ± 18.9</td>
<td>52.8 ± 16.3</td>
<td>34.7 ± 10.9</td>
<td>0.024*</td>
</tr>
<tr>
<td>Mean ± S.D. Median (Range)</td>
<td>44.5 (15 – 82)</td>
<td>52.5 (25 -75)</td>
<td>36 (20 – 59)</td>
<td></td>
</tr>
<tr>
<td>Sex</td>
<td>22 (56.4%)</td>
<td>4 (10.3%)</td>
<td>13 (33.3%)</td>
<td>0.002**</td>
</tr>
<tr>
<td>Males (%)</td>
<td>38 (82.6%)</td>
<td>6 (13.1%)</td>
<td>2 (4.3%)</td>
<td></td>
</tr>
<tr>
<td>Female s (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Family history</td>
<td>46 (83.6%)</td>
<td>9 (16.4%)</td>
<td>--</td>
<td>0.678***</td>
</tr>
<tr>
<td>Negative (%)</td>
<td>14 (93.3%)</td>
<td>1 (6.7%)</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Positive (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chronic illness</td>
<td>14 (66.7%)</td>
<td>7 (33.3%)</td>
<td>--</td>
<td>0.006***</td>
</tr>
<tr>
<td>Yes (%)</td>
<td>46 (93.9%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No (%)</td>
<td></td>
<td>3 (6.1%)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*P- value was calculated by Kruskal Wallis test
**P- value was calculated by Chi square test
***P- value was calculated by Fisher's Exact Test

Table (2): Comparison of Visfatin enzyme levels according to tumor burden (N. =60)

Visfatin level is proportionalycorrelted with tumor burden

<table>
<thead>
<tr>
<th>Enzyme</th>
<th>High (N=24)</th>
<th>Low (N=36)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Visfatin (µg/dl)</td>
<td>15.9 ± 2.7</td>
<td>14.02 ± 2.4</td>
<td>0.006*</td>
</tr>
<tr>
<td>Mean ± S.D. Median (Range)</td>
<td>16.8 (11.8 – 19.7)</td>
<td>14 (10.9 – 19.1)</td>
<td></td>
</tr>
</tbody>
</table>

*P- value was calculated by Mann–Whitney test
*Statistically significant.
Table (3): Comparison of Visfatin enzyme levels according to invasiveness and metastasis (N = 60) Visfatin level is proportionally correlated with invasiveness and metastasis

<table>
<thead>
<tr>
<th>Enzyme</th>
<th>Yes (N= 24)</th>
<th>No (N= 36)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Visfatin (µg/dl) Mean± S.D.</td>
<td>17.6 ± 1.3</td>
<td>12.9 ± 1.4</td>
<td>0.000*</td>
</tr>
<tr>
<td>Median (Range)</td>
<td>17.05 (15.1 – 19.7)</td>
<td>12.8 (10.9 – 15.5)</td>
<td></td>
</tr>
</tbody>
</table>

P-value was calculated by Mann–Whitney test *Statistically significant

Table (4): Comparison of Visfatin enzyme levels according to grade (N = 60) Visfatin level is proportionally correlated with tumor grade

<table>
<thead>
<tr>
<th>Enzyme</th>
<th>Grade 1 (N=2)</th>
<th>Grade 2 (N=46)</th>
<th>Grade 3 (N=12)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Visfatin (µg/dl) Mean± S.D. Median(Range)</td>
<td>14.4 ± 0.0 14.4 (14.4 – 14.4)</td>
<td>14.7 ± 2.7 14.1 (11 -19.7)</td>
<td>15.4 ± 3.1 16.8 (10.9–19.1)</td>
<td>0.867</td>
</tr>
</tbody>
</table>

P-value was calculated by Kruskal Wallis test.

Table (5): Comparison of Visfatin enzyme levels according to differentiation (N = 60) Visfatin level is proportionally correlated with tumor differentiation

<table>
<thead>
<tr>
<th>Enzyme</th>
<th>Poor differentiation (N=16)</th>
<th>Moderate differentiation (N=38)</th>
<th>Well differentiation (N=6)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Visfatin (µg/dl) Mean± S.D. Median(Range)</td>
<td>17.8 ± 1.8 18.1 (14.1 – 19.7)</td>
<td>13.9 ± 2.1 14 (10.9 -17.1)</td>
<td>12.5 ± 1.5 11.7 (11.3–14.4)</td>
<td>0.000*</td>
</tr>
</tbody>
</table>

P-value was calculated by Kruskal Wallis test *Statistically significant

Table (6): Comparison of Visfatin enzyme levels according to stage of cancer (N = 60) Visfatin level is proportionally correlated with stage of cancer

<table>
<thead>
<tr>
<th>Enzyme</th>
<th>Stage I (N=10)</th>
<th>Stage I I (N=32)</th>
<th>Stage I II (N=14)</th>
<th>Stage I V (N=4)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Visfatin (µg/dl) Mean± S.D. Median (Range)</td>
<td>12.4 ± 1.2 12.5 (11 – 14)</td>
<td>13.7 ± 1.9 14.1 (10.9 -17.1)</td>
<td>17.6 ± 1.05 17 (16.5–19.7)</td>
<td>19.4 ± 0.3 19.4 (19.1–19.7)</td>
<td>0.000*</td>
</tr>
</tbody>
</table>

P-value was calculated by Kruskal Wallis test *Statistically significant
Table (7): Comparison of Visfatin enzyme level among the study groups

<table>
<thead>
<tr>
<th>Enzyme</th>
<th>Malignant tumor (N=60)</th>
<th>Benign tumor (N=10)</th>
<th>Healthy control (N=15)</th>
<th>P-value</th>
<th>P1</th>
<th>P2</th>
<th>P3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Visfatin (µg/dl)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean± S.D.</td>
<td>14.8 ± 2.7</td>
<td>5.4 ± 1.8</td>
<td>2.7 ± 1.2</td>
<td>0.000*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median (Range)</td>
<td>14.3 (10.9 – 19.7)</td>
<td>5.6 (1.4 -8)</td>
<td>2.4 (1 – 5)</td>
<td></td>
<td>0.00*</td>
<td>1*</td>
<td>0.00</td>
</tr>
</tbody>
</table>

P-value compared the three groups and was calculated by Kruskal Wallis test.
P1 compared malignant and benign groups and was calculated by Mann–Whitney test
P2 compared benign and healthy control groups and was calculated by Mann–Whitney test
P3 compared malignant and healthy control groups and was calculated by Mann–Whitney test
*Statistically significant

Table (8): Comparison of Nitric oxide and lipid peroxide and superoxide dismutase enzyme level among the study groups

<table>
<thead>
<tr>
<th>Enzyme</th>
<th>Malignant tumor (N=60)</th>
<th>Benign tumor (N=10)</th>
<th>Healthy control (N=15)</th>
<th>P-value</th>
<th>P1</th>
<th>P2</th>
<th>P3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nitric oxide (Mmol/L)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean± S.D.</td>
<td>19.9 ± 2.9</td>
<td>8.9 ± 1.5</td>
<td>5.1 ± 0.6</td>
<td>0.000*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median (Range)</td>
<td>20.3 (15 – 25)</td>
<td>8.4 (7.4-12)</td>
<td>5 (4.1 – 6)</td>
<td></td>
<td>0.000*</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

P-value compared the three groups and was calculated by Kruskal Wallis test.
P1 compared malignant and benign groups and was calculated by Mann–Whitney test
P2 compared benign and healthy control groups and was calculated by Mann–Whitney test
P3 compared malignant and healthy control groups and was calculated by Mann–Whitney test
*Statistically significant
Discussion

Colorectal cancer (CRC) is the third most common cancer and the third leading cause of cancer death expected to occur in both men and women in the United States in 2014 (1) and accounted for almost 10% of global cancer incidence burden in 2012(2). Despite improvements in screening for early diagnosis, colorectal cancer remains one of the biggest cancer killers in the world and is responsible for over 600,000 deaths each year (3). There is growing support for the concept that reactive oxygen species (ROS) which are known to be implicated in a range of diseases, may be important progenitors in carcinogenesis (12). In the last decade, growing number of reports investigating association between ROS and carcinogenesis have been published (12,13,14). However, recent evidence has suggested that the generation of ROS may play important role in all phases of carcinogenesis, that is, the initiation, promotion, and progression stages (12).

Nicotinamide phosphoribosyltransferase (NAmPRTase or Nampt) also known as pre-B-cell colony-enhancing factor 1 (PBEF1) or visfatin is an enzyme that in humans is encoded by the PBEF1 gene, this protein has also been reported to be a cytokine (PBEF) that promotes B cell maturation and inhibits neutrophil apoptosis (5). The three major functions of NAMPT: growth factor, cytokine and nicotinamide phosphoribosyltransferase (9). Nampt is the rate-limiting enzyme that catalyzes the first step in NAD biosynthesis from nicotinamide by transferring the phosphoribosyl group of 5-phosphoribosyl-1-pyrophosphate to nicotinamide (NAM), forming NMN. NAD synthesis is completed by NMN adenyllyltransferase (Nmnat), which converts NMN into NAD (15).

In the present study we find that the serum levels of visfatin "NAMPT" in patients with benign tumor were significantly higher than in healthy controls, in patients with colorectal cancer the levels is significantly higher than in healthy controls and patients with benign tumor (p-value< 0.001) table(7) in patients with colorectal cancer, patients having advanced stage (III, IV) and whose tumor has high tumor burden and those having metastasing, invasiveness showed significantly higher visfatin levels compared with those with compared groups (I, II) (P-value <0.05) table(6), (2), (3) respectively.

The present findings are in agreement with previous research studies Nakajima et al (16) which showed that serum Nampt levels were significantly higher in 115 CC patients than in 115 age-, gender- and body mass index (BMI)-matched controls both in univariate (p<0.01) and multivariable analyses (OR: 2.95, 95% C.I. 1.862-4.787, p<0.01). In addition Nakajima et al., (16) reported that serum Nampt levels may represent a promising biomarker of CC malignant potential and stage progression. Circulating Nampt gradually increased with tumor stage progression (p<0.01) (16). Nampt was first reported to be overexpressed in colorectal cancer using suppression subtractive hybridization Hufton et al; (10).

Additionally plasma Nampt levels in patients with advanced and early cancer were higher than in controls (11). Xiaoqun et al; (17) reported that Nampt expression was significantly higher in human colorectal adenoma (P<0.05) and carcinoma (P<0.001), furthermore the
positive rate of Nampt expression in the malignant colorectal adenocarcinoma was higher than in the benign colorectal adenoma ($P<0.001$). In contrast to our study, Xiaoqun et al; (17) found that there is no correlation of Nampt expression with clinic-pathological features of CRC patients, such as gender, age, location, tumor size, clinical stages, depth of wall invasion, and lymph node metastasis.

In the present study we find that the levels of Nitric oxide, in patients with benign tumor were significantly higher than in healthy controls, in patients with colorectal cancer the levels is significantly higher than in healthy controls and patients with benign tumor ($p$-value $< 0.001$) table(8), also in patients with colorectal cancer, patients having advancing stage(III,IV) showed significantly higher Nitric oxide levels compared with those with early stag(I,II) ($P$-Value $<0.05$). Also the levels of Nitric oxide in cancer patients is higher in cases with metastasis than those with regional disease(no metastasis) ($p$-value $0.000$).

The present findings are in agreement with EL-Deek et al; (18), who reported that the levels of Nitric oxide in patients with benign colorectal tumor were significantly higher than in healthy controls, in patients with colorectal cancer the levels is significantly higher than in healthy controls and patients with benign tumor ($p$-value $< 0.001$), also in patients with colorectal cancer, having advancing stage(III,IV) showed significantly higher Nitric oxide levels compared with those with early stag(I,II) ($P$-Value $<0.05$). Also the levels of Nitric oxide in cancer patients is higher in cases with metastasis than those with regional disease(no metastasis), also in agreement with previous studies which showed that, NO activity and NO synthesis were high in colorectal tumors tissue and in plasma.

In the present study we find that the levels of lipid peroxide (MDA), in patients with benign tumor were significantly higher than in healthy controls, in patients with colorectal cancer the levels is significantly higher than in healthy controls and patients with benign tumor ($p$-value $< 0.05$) table(8).

Also we found that the levels of superoxide dismutase (SOD) in patients with benign tumor were significantly lower than in healthy controls, in patients with colorectal cancer the levels is significantly lower than in healthy controls and patients with benign tumor table(8).

The present findings are in agreement with Haklar et al; (19) who found that the human colorectal tumors (adenomas and carcinomas) have increased levels of different markers of oxidative stress, such as increased levels of ROS (measured by chemiluminescence), nitric oxide (NO). Also in the last decade, growing number of reports investigating association between ROS and carcinogenesis have been published (12,13,14). Observations similar to our findings have been reported in studies on colorectal cancer (17).

In conclusion, our study relieved that there is positive relation between level of visfatin and colorectal cancer occurrence and cancer clinicopathological criteria as proven, reported by (16). Also our study relieved that the levels of oxidant markers as (NO and lipid peroxidation products as "MDA") were highly elevated in colorectal cancer group, benign lesions group comparing to healthy control group, in contrast the levels of antioxidant enzyme (superoxide dismutase) where altered "decreased "in colorectal cancer group.
benign lesions group comparing to healthy control group as proven, reported by (15).

References
PATIENTS BEFORE AND AFTER TREATMENT in Indian Journal of Clinical Biochemistry, 19 (2) 80-83.


